Free Newsletter
Novavax, CPL complete Indian vax facility
A facility for the manufacture of vaccines using Novavax's virus-like particle technology is currently undergoing validation outside Ahmadabad, India. The plant has the capacity to produce 60 million doses per year.
CPL Biologicals, a joint venture Cadila Pharmaceuticals and Novavax, announced completion of construction. The JV plans to produce seasonal and pandemic flu vaccines.
Cadila says the VLP recombinant technology will permit fast vaccine-production response for pandemics. But CPL is still lacking Indian regulatory approval to conduct clinical trials in-country for VLP-based swine flu vaccine. Meanwhile, Indian drugmakers have recently come online as producers of egg-based flu vaccines.
- here's the article
Related Articles:
Novavax, Xcellerex double-team H1N1
Novavax shares the wealth
Novavax swiftly ramps up new India vax facility
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: